L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> S L1 fam full
FULL SEARCH INITIATED 10:00:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L2 1 SEA FAM FUL L1

=> D L2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 862589-32-0 REGISTRY
ED Entered STN: 07 Sep 2005
CN Benzenesulfonic acid, 2-[4-(aminocarbonyl)phenoxy]-5-[4-[(octadecylamino)carbonyl]-2-oxo-1-pyrrolidinyl]- (CA INDEX NAME)
MF C36 H53 N3 O7 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	70.10	70.76

FILE 'CAPLUS' ENTERED AT 10:00:22 ON 28 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Nov 2007 VOL 147 ISS 23
FILE LAST UPDATED: 27 Nov 2007 (20071127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s L2
L3 1 L2

=> D L3 ibib abs kwic hitstr

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:823449 CAPLUS <<LOGINID::20071128>>
DOCUMENT NUMBER: 143:229556
TITLE: Preparation and use of long-chain alkyl compounds as heparanase inhibitors
INVENTOR(S): Van Gelder, Joel M.; Basel, Yochai; Kraiz, Boris O.; Mouallem, Orly; Miron, Daphna; Gur-Arie, Nina; Klein, Joseph
PATENT ASSIGNEE(S): Insight Biopharmaceuticals Ltd., Israel
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074375	A2	20050818	WO 2005-IL149	20050206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005211255	A1	20050818	AU 2005-211255	20050206
CA 2555313	A1	20050818	CA 2005-2555313	20050206
EP 1720828	A2	20061115	EP 2005-703192	20050206
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2007525494	T	20070906	JP 2006-552017	20050206
US 2007185176	A1	20070809	US 2006-588554	20060807

PRIORITY APPLN. INFO.: US 2004-541904P P 20040206
WO 2005-IL149 W 20050206

OTHER SOURCE(S): CASREACT 143:229556; MARPAT 143:229556

GI



I



II



III



IV



V

AB The invention provides heparanase inhibitors I-IV (R1 = substituted 5-hydroxy-1-pyrazolyl, carboxamido, carbonylamino, alkylsulfonyl, aryloxy, etc; R2-R7 = independently H, halo, NO2, C1-32 alkyl, C2-32 alkenyl, C6-14 aryl, heteroaryl, alkoxy, thioalkyl, amino, alkylamino, acyl, acyloxy, etc.; or R1 and R2 may form heterocyclic ring; R8 = C1-32 alkyl; R9 = C2-32 alkenyl) suitable for treatment of diseases and disorders caused by or associated with heparanase catalytic activity such as cancer, inflammatory disorders and autoimmune diseases. Thus, long-chain amide V was prepared in

two steps from stearoyl chloride and di-Me 5-(2-amino-4-methoxycarbonylphenoxy)isophthalate. Amide V inhibited human recombinant heparanase with IC50 = 2.00 μM.

IT 32654-05-0P 57609-85-5P 862589-01-3P 862589-05-7P 862589-09-1P
862589-10-4P 862589-11-5P 862589-12-6P 862589-13-7P 862589-14-8P
862589-15-9P 862589-17-1P 862589-18-2P 862589-20-6P 862589-21-7P
862589-23-9P 862589-25-1P 862589-26-2P 862589-27-3P 862589-28-4P
862589-29-5P 862589-31-9P 862589-32-0P 862589-33-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and use of long-chain alkyl compds. as heparanase inhibitors)

IT 862589-32-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and use of long-chain alkyl compds. as heparanase inhibitors)

RN 862589-32-0 CAPLUS

CN Benzenesulfonic acid, 2-[4-(aminocarbonyl)phenoxy]-5-[4-[(octadecylamino)carbonyl]-2-oxo-1-pyrrolidinyl]- (CA INDEX NAME)



=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.02	77.78
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

STN INTERNATIONAL LOGOFF AT 10:02:01 ON 28 NOV 2007